---
document_datetime: 2026-02-17 10:31:25
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imbruvica-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imbruvica-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.6104795
conversion_datetime: 2026-02-21 12:49:29.836076
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Imbruvica

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber      | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|-------------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | Q.II.f.1.b)Extensionof theshelflifeof the | 13/02/2026                          |                                          | SmPC                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000327541                     | finished product - Q.II.f.1.b.1 As packaged for sale (supported by real time data, fully in line with the stability protocol) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |             |                                                                                     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000314319 | Thiswasanapplicationfor agroupof variations. B.III.1.bEuropeanPharmacopoeial TSE Certificate ofsuitabilityfor an active substance/startingmaterial/reagent/ intermediate/orexcipient-B.Ill.1.b.3 Updated certificate from an already approved manufacturer - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediateusedinthe manufacturingprocessofthe active substance -B.I.b.2.a Minor changes to an approved test procedure- Accepted B.III.1.bEuropeanPharmacopoeial TSE Certificateofsuitabilityfor an active substance/starting material/reagent/ intermediate/orexcipient-B.IIl.1.b.3 Updated certificate from an already approved manufacturer-Accepted | 15/12/2025 |             |                                                                                     |
| Variation type II / EMA/VR/0000281739 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, LabellingorPackageLeafletduetonew quality, preclinical, clinical or pharmacovigilancedata-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/09/2025 | SmPC and PL | Not applicable.Formoreinformation,pleaserefer totheSummaryofProductCharacteristics. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                       | Update of section 4.8 of the SmPC in order to add \"uveitis\" to the list of adverse drug reactions (ADRs) with frequency \"uncommon\" based on post-marketing data. The Package Leaflet is updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IB / EMA/VR/0000268748 | This was an application for a group of variations. B.I1.b.5 Change toin-process tests orlimits applied during the manufacture of the finishedproduct-B.II.b.5.zOtherchanges- Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of thefinishedproduct-B.Il.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originallyapprovedbatchsize-Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediateusedinthemanufactureofthe finishedproduct-B.II.b.3.aMinor change in the manufacturing process - Accepted B.II.b.1Replacement or addition of a manufacturingsiteforpartor all ofthe manufacturing process of the finished | 18/06/2025 |

<div style=\"page-break-after: always\"></div>

| manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for nonsterile medicinal products - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|